CYP2C9 Gene (Protein Coding)

Cytochrome P450 Family 2 Subfamily C Member 9

GC10P094938
GIFtS:
50
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobioti... See more...

Aliases for CYP2C9 Gene

Aliases for CYP2C9 Gene

  • Cytochrome P450 Family 2 Subfamily C Member 9 2 3 5
  • Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 2 3
  • Cytochrome P450 PB-1 3 4
  • Cytochrome P450 2C9 3 4
  • Cytochrome P-450MP 3 4
  • EC 1.14.14.1 4 50
  • P450IIC9 2 3
  • CYP2C10 3 4
  • CYPIIC9 3 4
  • Cytochrome P450, Subfamily IIC (Mephenytoin 4-Hydroxylase), Polypeptide 9 2
  • Cytochrome P-450 S-Mephenytoin 4-Hydroxylase 3
  • Flavoprotein-Linked Monooxygenase 3
  • (R)-Limonene 6-Monooxygenase 4
  • (S)-Limonene 6-Monooxygenase 4
  • (S)-Limonene 7-Monooxygenase 4
  • S-Mephenytoin 4-Hydroxylase 4
  • Cholesterol 25-Hydroxylase 4
  • Microsomal Monooxygenase 3
  • Xenobiotic Monooxygenase 3
  • Cytochrome P450 MP-4 4
  • Cytochrome P450 MP-8 4
  • EC 1.14.14.53 4
  • EC 1.14.14.51 4
  • EC 1.14.14.52 4
  • CYP2C9 5
  • CYP2C 3
  • CPC9 3

External Ids for CYP2C9 Gene

Previous HGNC Symbols for CYP2C9 Gene

  • CYP2C10

Previous GeneCards Identifiers for CYP2C9 Gene

  • GC10P095591
  • GC10P095932
  • GC10P096829
  • GC10P096363
  • GC10P096688
  • GC10P090325

Summaries for CYP2C9 Gene

Entrez Gene Summary for CYP2C9 Gene

  • This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008]

GeneCards Summary for CYP2C9 Gene

CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) is a Protein Coding gene. Diseases associated with CYP2C9 include Coumarin Resistance and Diffuse Alveolar Hemorrhage. Among its related pathways are Naphthalene metabolism and Arachidonic acid metabolism. Gene Ontology (GO) annotations related to this gene include oxidoreductase activity and heme binding. An important paralog of this gene is CYP2C19.

UniProtKB/Swiss-Prot Summary for CYP2C9 Gene

  • A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:7574697, PubMed:15766564, PubMed:19965576, PubMed:9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9866708, PubMed:9435160). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031).

Gene Wiki entry for CYP2C9 Gene

PharmGKB "VIP" Summary for CYP2C9 Gene

Additional gene information for CYP2C9 Gene

No data available for CIViC Summary , Tocris Summary , Rfam classification and piRNA Summary for CYP2C9 Gene

Genomics for CYP2C9 Gene

GeneHancer (GH) Regulatory Elements Pubs

Download GeneHancer 2017 data
Promoters and enhancers for CYP2C9 Gene
GeneHancer (GH) Identifier GH Type GH
Score		 GH Sources Gene Association Score Total Score TSS distance (kb) Number of Genes Away Size (kb) Transcription Factor
Binding Sites		 Gene Targets
GH10J094901 Promoter/Enhancer 1.3 EPDnew Ensembl ENCODE 250.3 -35.0 -34969 4.7 CEBPA ATF3 CHD4 YY1 CEBPB HOMEZ THAP11 FOXA2 KDM6A SMAD4 CYP2C9 ACSM6 CYP2C19 CYP2C115P HSALNG0079820 piR-47086-042 MN309174-059
GH10J094938 Promoter 0.7 EPDnew 250.7 0.0 -19 0.1 YY1 RXRA JUND HNF4A FOXA1 RAD21 REST MAX SP1 TAF1 CYP2C9 HSALNG0079821 HSALNG0079820 CYP2C19 MN309174-059
GH10J094679 Promoter/Enhancer 1.5 EPDnew Ensembl ENCODE 4.7 -256.2 -256227 5.9 CEBPA ATF3 YY1 CEBPB HOMEZ EP300 THAP11 FOXA2 RXRA SAP130 CYP2C18 ACSM6 CYP2C19 MTND4P19 NOC3L CYP2C9 HSALNG0079815 HELLS
GH10J094212 Enhancer 0.8 Ensembl ENCODE 4 -724.8 -724796 2.7 CEBPA ATF3 POLR2A YY1 CEBPB FOXA2 RXRA ZBTB33 USF2 FOSL2 NOC3L MTND4P19 HELLS CYP2C9 ENSG00000228553 piR-58308-044 PLCE1
GH10J095331 Enhancer 0.9 FANTOM5 Ensembl dbSUPER 1.6 +392.0 392043 1.8 FOXA2 CTBP1 PKNOX1 FOXA1 DPF2 CREB1 RXRA SORBS1 CYP2C8 CYP2C9 HSALNG0079840 PDLIM1 lnc-PDLIM1-4 lnc-SORBS1-1
- Elite GeneHancer and/or Elite GeneHancer-gene association Download GeneHancer data from 2017 publication | Request up-to-date GeneHancer data (full dataset)

GeneHancers around CYP2C9 on the GeneHancer Hub at the UCSC Golden Path

Cistromic (ChIP-Seq) regulation report from SPP (The Signaling Pathways Project) for CYP2C9

Top Transcription factor binding sites by QIAGEN in the CYP2C9 gene promoter:
  • COUP
  • COUP-TF
  • COUP-TF1
  • GATA-1
  • HNF-4alpha1
  • HNF-4alpha2
  • HOXA5
  • PPAR-gamma1
  • PPAR-gamma2

Genomic Locations for CYP2C9 Gene

Latest Assembly
chr10:94,938,658-94,990,091
(GRCh38/hg38)
Size:
51,434 bases
Orientation:
Plus strand

Previous Assembly
chr10:96,698,415-96,749,848
(GRCh37/hg19 by Entrez Gene)
Size:
51,434 bases
Orientation:
Plus strand

chr10:96,698,415-96,749,147
(GRCh37/hg19 by Ensembl)
Size:
50,733 bases
Orientation:
Plus strand

Genomic View for CYP2C9 Gene

Genes around CYP2C9 on UCSC Golden Path with GeneCards custom track

Cytogenetic band:
CYP2C9 Gene in genomic location: bands according to Ensembl, locations according to GeneLoc (and/or Entrez Gene and/or Ensembl if different)
Genomic Location for CYP2C9 Gene
GeneLoc Logo Genomic Neighborhood • Exon Structure • Gene Density

RefSeq DNA sequence for CYP2C9 Gene

Proteins for CYP2C9 Gene

Products:

  1. Antibodies for research
  2. Protein products for research
  3. Assay products for research

  • Protein details for CYP2C9 Gene (UniProtKB/Swiss-Prot)

    Protein Symbol:
    P11712-CP2C9_HUMAN
    Recommended name:
    Cytochrome P450 2C9
    Protein Accession:
    P11712
    Secondary Accessions:
    • P11713
    • Q16756
    • Q16872
    • Q5VX92
    • Q6IRV8
    • Q8WW80

    Protein attributes for CYP2C9 Gene

    Size:
    490 amino acids
    Molecular mass:
    55628 Da
    Cofactor:
    Name=heme; Xref=ChEBI:CHEBI:30413;
    Quaternary structure:
    No Data Available

    Three dimensional structures from OCA and Proteopedia for CYP2C9 Gene

    Alternative splice isoforms for CYP2C9 Gene

    UniProtKB/Swiss-Prot:

neXtProt entry for CYP2C9 Gene

Protein Expression for CYP2C9 Gene

See protein expression from ProteomicsDB, MOPED, PaxDb, and MaxQB

Selected DME Specific Peptides for CYP2C9 Gene

P11712:
  • CLVEELRK
  • LTSVLHD
  • FGMGKRS
  • YGPVFTLY
  • EEFSGRG
  • EKVKEHQ
  • GMGKRSIE
  • PFSAGKR
  • PGPTPLP
  • GKRICVGE
  • LLLLLKHP
  • IEDRVQEEA
  • LPHAVTCD
  • RRFSLMTL
  • KEFPNPE
  • GYEAVKEAL
  • CDPTFIL
  • EEIERVIG
  • GKLPPGP
  • VVLVLCLS
  • TTSTTLRY
  • DIKFRNY
  • AGTETTS
  • KFRNYLIPKGT
  • TAKVQEEI
  • PCNVICS

Post-translational modifications for CYP2C9 Gene

  • Modification sites at PhosphoSitePlus
  • Modification sites at neXtProt

Other Protein References for CYP2C9 Gene

ENSEMBL proteins:
REFSEQ proteins:

Domains & Families for CYP2C9 Gene

Gene Families for CYP2C9 Gene

HGNC:
IUPHAR :
Human Protein Atlas (HPA):
  • Enzymes
  • Predicted intracellular proteins

Protein Domains for CYP2C9 Gene

InterPro:
Blocks:
  • E-class P450 group I signature
  • CYP2B P450 family signature

Suggested Antigen Peptide Sequences for CYP2C9 Gene

GenScript: Design optimal peptide antigens:
  • S-mephenytoin 4-hydroxylase (CP2C9_HUMAN)
  • Cytochrome p4502C9 (Q5EDC5_HUMAN)
  • cDNA FLJ75561, highly similar to Homo sapiens cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9), mRNA (Q5VX92_HUMAN)
  • CYP2C9 protein (Q6IRV8_HUMAN)
  • Cytochrome P450, family 2, subfamily C, polypeptide 9, isoform CRA_a (Q8WW80_HUMAN)

Graphical View of Domain Structure for InterPro Entry

P11712

UniProtKB/Swiss-Prot:

CP2C9_HUMAN :
  • Belongs to the cytochrome P450 family.
Family:
  • Belongs to the cytochrome P450 family.
genes like me logo Genes that share domains with CYP2C9: view

Function for CYP2C9 Gene

Products:

  1. Animal Models for research
  2. CRISPR products for research
  3. miRNA products for research
  4. Inhibitory RNAs for research
  5. Clone products for research
  6. Cell Lines for research

Molecular function for CYP2C9 Gene

UniProtKB/Swiss-Prot Function:
A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:7574697, PubMed:15766564, PubMed:19965576, PubMed:9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9866708, PubMed:9435160). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031).
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=an organic molecule + O2 + reduced [NADPH--hemoprotein reductase] = an alcohol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:17149, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30879, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:142491; EC=1.14.14.1; Evidence={ECO:0000269|PubMed:12865317, ECO:0000269|PubMed:21576599, ECO:0000269|PubMed:9435160, ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (8R,9S)-epoxy-(5Z,11Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49884, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131975; Evidence={ECO:0000269|PubMed:7574697};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (8S,9R)-epoxy-(5Z,11Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49928, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131974; Evidence={ECO:0000269|PubMed:7574697};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (11R,12S)-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49880, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131970; Evidence={ECO:0000269|PubMed:7574697};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (11S,12R)-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49876, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131969; Evidence={ECO:0000269|PubMed:7574697};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (14R,15S)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49860, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131965; Evidence={ECO:0000269|PubMed:19965576, ECO:0000269|PubMed:7574697};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (14S,15R)-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:49856, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:131964; Evidence={ECO:0000269|PubMed:19965576, ECO:0000269|PubMed:7574697};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 8,9-epoxy-(5Z,11Z,14Z,17Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52168, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:136439; Evidence={ECO:0000269|PubMed:15766564};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 11,12-epoxy-(5Z,8Z,14Z,17Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52172, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:136441; Evidence={ECO:0000269|PubMed:15766564};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = 14,15-epoxy-(5Z,8Z,11Z,17Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52176, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:136443; Evidence={ECO:0000269|PubMed:15766564};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate + O2 + reduced [NADPH--hemoprotein reductase] = (17R,18S)-epoxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39779, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:58562, ChEBI:CHEBI:76634; Evidence={ECO:0000269|PubMed:15766564, ECO:0000269|PubMed:19965576};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=cholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 25-hydroxycholesterol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:50256, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16113, ChEBI:CHEBI:42977, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:21576599};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=17beta-estradiol + O2 + reduced [NADPH--hemoprotein reductase] = 2-hydroxy-17beta-estradiol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47212, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:16469, ChEBI:CHEBI:28744, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=estrone + O2 + reduced [NADPH--hemoprotein reductase] = 2-hydroxyestrone + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:47208, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:1156, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:17263, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; Evidence={ECO:0000269|PubMed:12865317};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (11R)-hydroxy-(5Z,8Z,12E,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52492, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:78836; Evidence={ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (12R)-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52300, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:83343; Evidence={ECO:0000269|PubMed:9435160, ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = (15R)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52496, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:78837; Evidence={ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 10-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52296, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:133345; Evidence={ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(9Z,12Z)-octadecadienoate + O2 + reduced [NADPH--hemoprotein reductase] = (13R)-hydroxy-(9Z,11E)-octadecadienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52500, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30245, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136655; Evidence={ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(9Z,12Z)-octadecadienoate + O2 + reduced [NADPH--hemoprotein reductase] = 9(R)-hydroxy-(10E,12Z)-octadecadienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52504, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:30245, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:77895; Evidence={ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 19-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:39759, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76627; Evidence={ECO:0000269|PubMed:9435160, ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 13(S)-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52508, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136654; Evidence={ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:51472, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:84024; Evidence={ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:51480, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:76625; Evidence={ECO:0000269|PubMed:9866708};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + O2 + reduced [NADPH--hemoprotein reductase] = 13-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:52292, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:32395, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210, ChEBI:CHEBI:136524; Evidence={ECO:0000269|PubMed:9435160};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4R)-limonene + O2 + reduced [NADPH--hemoprotein reductase] = (1R,5S)-carveol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:18957, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:15382, ChEBI:CHEBI:15388, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.53; Evidence={ECO:0000269|PubMed:11950794};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4S)-limonene + O2 + reduced [NADPH--hemoprotein reductase] = (1S,5R)-carveol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:17945, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:15383, ChEBI:CHEBI:15389, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.51; Evidence={ECO:0000269|PubMed:11950794};.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=(4S)-limonene + O2 + reduced [NADPH--hemoprotein reductase] = (4S)-perillyl alcohol + H(+) + H2O + oxidized [NADPH--hemoprotein reductase]; Xref=Rhea:RHEA:23432, Rhea:RHEA-COMP:11964, Rhea:RHEA-COMP:11965, ChEBI:CHEBI:10782, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15379, ChEBI:CHEBI:15383, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210; EC=1.14.14.52; Evidence={ECO:0000269|PubMed:11950794};.
UniProtKB/Swiss-Prot Induction:
By rifampicin.
UniProtKB/Swiss-Prot BiophysicochemicalProperties:
Kinetic parameters: KM=12.2 uM for (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate (epoxygenation) {ECO:0000269|PubMed:15766564}; KM=14.3 uM for (5Z,8Z,11Z,14Z)-eicosatetraenoate (epoxygenation) {ECO:0000269|PubMed:15766564}; KM=1.25 mM for S-mephenytoin {ECO:0000269|PubMed:3079764}; KM=46.24 uM for tolbutamide {ECO:0000269|PubMed:25994031}; KM=4.73 uM for diclofenac {ECO:0000269|PubMed:25994031}; KM=1.58 uM for losartan {ECO:0000269|PubMed:25994031}; Vmax=210.30 pmol/min/pmol enzyme with losartan as substrate {ECO:0000269|PubMed:25994031}; Vmax=29.1 nmol/min/nmol enzyme toward (5Z,8Z,11Z,14Z,17Z)-eicosapentaenoate (epoxidation) {ECO:0000269|PubMed:15766564}; Vmax=29.2 nmol/min/nmol enzyme toward (5Z,8Z,11Z,14Z)-eicosatetraenoate (epoxidation) {ECO:0000269|PubMed:15766564}; Vmax=9.22 pmol/min/pmol enzyme with tolbutamide as substrate {ECO:0000269|PubMed:25994031}; Vmax=17.16 pmol/min/pmol enzyme with diclofenac as substrate {ECO:0000269|PubMed:25994031};
GENATLAS Biochemistry:
cytochrome P450,subfamily IIC (mephenytoin 4-hydroxylase),polypeptide 9

Enzyme Numbers (IUBMB) for CYP2C9 Gene

Phenotypes From GWAS Catalog for CYP2C9 Gene

Gene Ontology (GO) - Molecular Function for CYP2C9 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0004497 monooxygenase activity NAS 2827463
GO:0005506 iron ion binding IEA --
GO:0008392 arachidonic acid epoxygenase activity IDA 7574697
GO:0008395 steroid hydroxylase activity IMP 18356043
GO:0016491 oxidoreductase activity IDA 16401082
genes like me logo Genes that share ontologies with CYP2C9: view
genes like me logo Genes that share phenotypes with CYP2C9: view

Human Phenotype Ontology for CYP2C9 Gene

HPO Id HPO Name Alternative Ids Definition Synonyms

Animal Models for research

miRNA for CYP2C9 Gene

miRTarBase miRNAs that target CYP2C9

Inhibitory RNAs for research

  • Search GeneCopoeia for shRNA, lentivirus and/or AAV clone products for CYP2C9

No data available for Animal Models , Transcription Factor Targets and HOMER Transcription for CYP2C9 Gene

Localization for CYP2C9 Gene

Subcellular locations from UniProtKB/Swiss-Prot for CYP2C9 Gene

Endoplasmic reticulum membrane. Peripheral membrane protein. Microsome membrane. Peripheral membrane protein.

Subcellular locations from

COMPARTMENTS
Extracellular space Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi Apparatus Nucleus Mitochondrion 0 1 2 3 4 5 Confidence
COMPARTMENTS Subcellular localization image for CYP2C9 gene
Compartment Confidence
endoplasmic reticulum 3
plasma membrane 2
extracellular 2
cytoskeleton 2
mitochondrion 2
peroxisome 2
nucleus 2
cytosol 2
endosome 1
lysosome 1
golgi apparatus 1

Gene Ontology (GO) - Cellular Components for CYP2C9 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0005737 cytoplasm IBA 21873635
GO:0005783 endoplasmic reticulum IEA --
GO:0005789 endoplasmic reticulum membrane TAS --
GO:0016020 membrane IEA --
GO:0031090 organelle membrane IEA --
genes like me logo Genes that share ontologies with CYP2C9: view

No data available for Subcellular locations from the Human Protein Atlas (HPA) for CYP2C9 Gene

Pathways & Interactions for CYP2C9 Gene

PathCards logo

SuperPathways for CYP2C9 Gene

SuperPathway Contained pathways
1 Drug metabolism - cytochrome P450
Drug metabolism - cytochrome P450
.70
Metabolism of xenobiotics by cytochrome P450
.70
Chemical carcinogenesis
.68
Retinol metabolism
.33
Retinol metabolism
.31
Celecoxib Pathway, Pharmacokinetics
.01
Fluoxetine Pathway, Pharmacokinetics
.01
Haloperidol Pathway, Pharmacokinetics
.01
Ifosfamide Pathway, Pharmacokinetics
.01
Naproxen Pathway, Pharmacokinetics
.01
Sertraline Pathway, Pharmacokinetics
.01
Voriconazole Pathway, Pharmacokinetics
.01
Benzo[a]pyrene metabolism
.01
2 Cytochrome P450 - arranged by substrate type
Cytochrome P450 - arranged by substrate type
.64
Oxidation by Cytochrome P450
.64
Phase 1 - Functionalization of compounds
.63
Biological oxidations
.49
Xenobiotics
.39
Metapathway biotransformation
.36
Cannabidiol Pathway, Pharmacokinetics
.01
Doxepin Pathway, Pharmacokinetics
.01
CYP2E1 reactions
.01
Estradiol metabolism
.01
Vitamin D2 (ergocalciferol) metabolism
.01
3 Statin Pathway - Generalized, Pharmacokinetics
Ibuprofen Pathway, Pharmacokinetics
.42
Statin Pathway - Generalized, Pharmacokinetics
.42
Diclofenac Pathway, Pharmacokinetics
.39
Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics
.01
Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
.01
Clobazam Pathway, Pharmacokinetics
.01
Fluvastatin Pathway, Pharmacokinetics
.01
Rosiglitazone Pathway, Pharmacokinetics
.01
4 Imipramine/Desipramine Pathway, Pharmacokinetics
Amitriptyline and Nortriptyline Pathway, Pharmacokinetics
.50
Warfarin Pathway, Pharmacokinetics
.40
Clozapine Pathway, Pharmacokinetics
.38
Nevirapine Pathway, Pharmacokinetics
.38
Candesartan Pathway, Pharmacokinetics
.01
Metoprolol Pathway, Pharmacokinetics
.01
5 Metabolism
Metabolic pathways
.40
Metabolism
.40
Metabolism of lipids and lipoproteins
.37
genes like me logo Genes that share pathways with CYP2C9: view

UniProtKB/Swiss-Prot P11712-CP2C9_HUMAN

  • Pathway: Lipid metabolism; arachidonate metabolism.
  • Pathway: Steroid metabolism; cholesterol metabolism.
  • Pathway: Terpene metabolism; (4R)-limonene degradation.

Gene Ontology (GO) - Biological Process for CYP2C9 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0006082 organic acid metabolic process IBA 21873635
GO:0006629 lipid metabolic process IEA --
GO:0006805 xenobiotic metabolic process TAS --
GO:0008202 steroid metabolic process IMP 18356043
GO:0008203 cholesterol metabolic process IEA --
genes like me logo Genes that share ontologies with CYP2C9: view

No data available for SIGNOR curated interactions for CYP2C9 Gene

Drugs & Compounds for CYP2C9 Gene

Products:

  1. Drug products for research

(543) Drugs for CYP2C9 Gene - From: DrugBank, PharmGKB, ClinicalTrials, ApexBio, HMDB, and Novoseek

Name Status Disease Links Group Role Mechanism of Action Clinical Trials
Acenocoumarol Approved, Investigational Pharma Enzyme, substrate 46
Celecoxib Approved, Investigational Pharma Enzyme, substrate Selective cyclooxygenase-2 (COX-2) inhibitor 561
Flurbiprofen Approved, Investigational Pharma Enzyme, substrate 78
Ibuprofen Approved Pharma Enzyme, substrate 758
Meloxicam Approved, Vet_approved Pharma Enzyme, substrate 113

(99) Additional Compounds for CYP2C9 Gene - From: HMDB and Novoseek

Name Synonyms Role CAS Number PubChem IDs PubMed IDs
4'-Hydroxydiclofenac
  • (O-(2,6-Dichloro-4-hydroxyanilino)phenyl)acetic acid
  • 4'-Hydroxy diclofenac
  • 4'-OH DCF
  • (O-(2,6-Dichloro-4-hydroxyanilino)phenyl)acetate
  • {2-[(2,6-dichloro-4-hydroxyphenyl)amino]phenyl}acetic acid
 64118-84-9
Paraxanthine
  • 3,7-Dihydro-1,7-dimethyl-1H-purine-2,6-dione
  • p-Xanthine
  • 1,7-Dimethyl-xanthine
  • 1,7-Dimethylxanthine
 611-59-6
(-)-Limonene
  • (-)-(S)-Limonene
  • (-)-(4S)-Limonene
  • (4S)-1-Methyl-4-isopropenylcyclohex-1-ene
  • (4S)-4-Isopropenyl-1-methylcyclohexene
  • (S)-(-)-p-Mentha-1,8-diene
 5989-54-8
(-)-trans-Carveol
  • (-)-(4R,6S)-trans-Carveol
  • (1S,5R)-Carveol
  • Carveol
  • (-)-(4R,6S)-Carveol
  • (-)-trans-Carveol
 2102-58-1
(+)-trans-Carveol
  • (1R,5S)-Carveol
  • (4S,6R)-trans-Carveol
  • (+)-trans-Carveol
  • (1R,5S)-2-Methyl-5-(1-methylethenyl)-2-cyclohexen-1-ol
  • (E)-Carveol
 18383-51-2

(3) ApexBio Compounds for CYP2C9 Gene

Compound Action Cas Number
Amiodarone HCl Anti-arrhythmic drug 19774-82-4
Benzbromarone 3562-84-3
Gemfibrozil 25812-30-0
genes like me logo Genes that share compounds with CYP2C9: view

Drug products for research

Transcripts for CYP2C9 Gene

Products:

  1. CRISPR products for research
  2. miRNA products for research
  3. Inhibitory RNAs for research
  4. Clone products for research

mRNA/cDNA for CYP2C9 Gene

1 REFSEQ mRNAs :
15 NCBI additional mRNA sequence :
5 Ensembl transcripts including schematic representations, and UCSC links to gene/alias where relevant :

Inhibitory RNAs for research

  • Search GeneCopoeia for shRNA, lentivirus and/or AAV clone products for CYP2C9

Alternative Splicing Database (ASD) splice patterns (SP) for CYP2C9 Gene

ExUns: 1a · 1b · 1c ^ 2a · 2b ^ 3a · 3b ^ 4 ^ 5a · 5b ^ 6 ^ 7 ^ 8 ^ 9
SP1: - -
SP2: - - -
SP3: -
SP4:

Relevant External Links for CYP2C9 Gene

GeneLoc Exon Structure for
CYP2C9

Expression for CYP2C9 Gene

Products:

  1. Primer products for research
  2. Gene Expression Assays for research

mRNA expression in normal human tissues from GTEx, Illumina, BioGPS, and SAGE for CYP2C9 Gene

mRNA expression in normal human tissues for CYP2C9 Gene
mRNA expression by BioGPS for CYP2C9 GenemRNA expression by GTEx for CYP2C9 Gene

mRNA expression in embryonic tissues and stem cells from LifeMap Discovery

mRNA differential expression in normal tissues according to GTEx for CYP2C9 Gene

This gene is overexpressed in Liver (x49.5).

Protein differential expression in normal tissues from HIPED for CYP2C9 Gene

This gene is overexpressed in Gallbladder (43.7) and Liver (24.5).

Integrated Proteomics: protein expression in normal tissues and cell lines from ProteomicsDB and MOPED for CYP2C9 Gene



Protein tissue co-expression partners for CYP2C9 Gene

- Elite partner

Transcriptomic regulation report from SPP (The Signaling Pathways Project) for CYP2C9

SOURCE GeneReport for Unigene cluster for CYP2C9 Gene:

Hs.282624

Evidence on tissue expression from TISSUES for CYP2C9 Gene

  • Heart(5)
  • Liver(5)
  • Kidney(4.5)
  • Blood(3)
  • Intestine(3)
  • Urine(2.5)
  • Stomach(2.5)
  • Skin(2.3)
  • Nervous system(2.2)
  • Gall bladder(2)

Phenotype-based relationships between genes and organs from Gene ORGANizer for CYP2C9 Gene

Germ Layers:
  • mesoderm
Systems:
  • cardiovascular
  • digestive
  • immune
  • lymphatic
Regions:
Thorax:
  • thymus
Abdomen:
  • liver
  • spleen
General:
  • blood
  • bone marrow
  • coagulation system
  • red blood cell
  • white blood cell
genes like me logo Genes that share expression patterns with CYP2C9: view

Primer products for research

No data available for mRNA Expression by UniProt/SwissProt for CYP2C9 Gene

Orthologs for CYP2C9 Gene

This gene was present in the common ancestor of animals.

Orthologs for CYP2C9 Gene

Organism Taxonomy Gene Similarity Type Details
Chimpanzee
(Pan troglodytes)
 Mammalia LOC100616515 29
  • 99.46 (n)
CYP2C9 30
  • 99 (a)
 OneToOne
Cow
(Bos Taurus)
 Mammalia LOC505468 29
  • 83.79 (n)
-- 30
  • 79 (a)
 ManyToMany
CYP2C87 30
  • 78 (a)
 ManyToMany
CYP2C18 30
  • 78 (a)
 ManyToMany
-- 30
  • 77 (a)
 ManyToMany
Rat
(Rattus norvegicus)
 Mammalia Cyp2c11 29
  • 80.75 (n)
Mouse
(Mus musculus)
 Mammalia Cyp2c66 29 16 30
  • 80.54 (n)
 ManyToMany
Cyp2c65 16 30
  • 76 (a)
 ManyToMany
Cyp2c29 30
  • 76 (a)
 ManyToMany
Cyp2c39 30
  • 73 (a)
 ManyToMany
Cyp2c50 30
  • 73 (a)
 ManyToMany
Cyp2c37 30
  • 73 (a)
 ManyToMany
Cyp2c38 30
  • 72 (a)
 ManyToMany
Cyp2c54 30
  • 71 (a)
 ManyToMany
Cyp2c69 30
  • 67 (a)
 ManyToMany
Cyp2c67 30
  • 67 (a)
 ManyToMany
Cyp2c68 30
  • 66 (a)
 ManyToMany
Cyp2c40 30
  • 63 (a)
 ManyToMany
Oppossum
(Monodelphis domestica)
 Mammalia -- 30
  • 68 (a)
 ManyToMany
-- 30
  • 67 (a)
 ManyToMany
-- 30
  • 67 (a)
 ManyToMany
-- 30
  • 65 (a)
 ManyToMany
-- 30
  • 64 (a)
 ManyToMany
Fruit Fly
(Drosophila melanogaster)
 Insecta Cyp18a1 31
  • 32 (a)
Cyp303a1 31
  • 26 (a)
Worm
(Caenorhabditis elegans)
 Secernentea F42A9.5 31
  • 34 (a)
B0213.14 31
  • 33 (a)
C12D5.7 31
  • 33 (a)
F41B5.3 31
  • 33 (a)
B0213.12 31
  • 33 (a)
B0213.10 31
  • 32 (a)
C49C8.4 31
  • 32 (a)
F41B5.7 31
  • 32 (a)
F44C8.1 31
  • 32 (a)
K09A11.3 31
  • 32 (a)
T10H4.11 31
  • 32 (a)
Y49C4A.9 31
  • 32 (a)
B0304.3 31
  • 31 (a)
C34B7.3 31
  • 31 (a)
C41G6.1 31
  • 31 (a)
C45H4.17 31
  • 31 (a)
F41B5.2 31
  • 31 (a)
F41B5.4 31
  • 31 (a)
T10H4.10 31
  • 31 (a)
T09H2.1 31
  • 31 (a)
C45H4.2 31
  • 31 (a)
B0213.15 31
  • 30 (a)
F14H3.10 31
  • 30 (a)
K09D9.2 31
  • 30 (a)
C03G6.15 31
  • 29 (a)
C49G7.8 31
  • 29 (a)
K07C6.2 31
  • 29 (a)
K07C6.3 31
  • 29 (a)
K07C6.5 31
  • 29 (a)
R08F11.3 31
  • 29 (a)
B0213.16 31
  • 29 (a)
C25E10.2 31
  • 28 (a)
Y5H2B.6 31
  • 28 (a)
Species where no ortholog for CYP2C9 was found in the sources mined by GeneCards:
  • A. gosspyii yeast (Eremothecium gossypii)
  • Actinobacteria (Mycobacterium tuberculosis)
  • African clawed frog (Xenopus laevis)
  • African malaria mosquito (Anopheles gambiae)
  • Alicante grape (Vitis vinifera)
  • Alpha proteobacteria (Wolbachia pipientis)
  • Amoeba (Dictyostelium discoideum)
  • Archea (Pyrococcus horikoshii)
  • Baker's yeast (Saccharomyces cerevisiae)
  • Barley (Hordeum vulgare)
  • Beta proteobacteria (Neisseria meningitidis)
  • Bread mold (Neurospora crassa)
  • Chicken (Gallus gallus)
  • Chromalveolata (Phytophthora infestans)
  • Common water flea (Daphnia pulex)
  • Corn (Zea mays)
  • Dog (Canis familiaris)
  • E. coli (Escherichia coli)
  • Filamentous fungi (Aspergillus nidulans)
  • Firmicute Bacteria (Streptococcus pneumoniae)
  • Fission Yeast (Schizosaccharomyces pombe)
  • Green Algae (Chlamydomonas reinhardtii)
  • Honey Bee (Apis mellifera)
  • K. Lactis Yeast (Kluyveromyces lactis)
  • Lizard (Anolis carolinensis)
  • Loblloly Pine (Pinus taeda)
  • Malaria Parasite (Plasmodium falciparum)
  • Medicago Trunc (Medicago Truncatula)
  • Moss (Physcomitrella patens)
  • Orangutan (Pongo pygmaeus)
  • Pig (Sus scrofa)
  • Platypus (Ornithorhynchus anatinus)
  • Rainbow Trout (Oncorhynchus mykiss)
  • Rice (Oryza sativa)
  • Rice Blast Fungus (Magnaporthe grisea)
  • Schistosome Parasite (Schistosoma mansoni)
  • Sea Anemone (Nematostella vectensis)
  • Sea Vase (Ciona intestinalis)
  • Sea Squirt (Ciona savignyi)
  • Sea Urchin (Strongylocentrotus purpuratus)
  • Sorghum (Sorghum bicolor)
  • Soybean (Glycine max)
  • Stem Rust Fungus (Puccinia graminis)
  • Sugarcane (Saccharum officinarum)
  • Thale Cress (Arabidopsis thaliana)
  • Tomato (Lycopersicon esculentum)
  • Toxoplasmosis (Toxoplasma gondii)
  • Trichoplax (Trichoplax adhaerens)
  • Tropical Clawed Frog (Silurana tropicalis)
  • Wheat (Triticum aestivum)
  • Zebrafish (Danio rerio)

Evolution for CYP2C9 Gene

ENSEMBL:
Gene Tree for CYP2C9 (if available)
TreeFam:
Gene Tree for CYP2C9 (if available)
Aminode:
Evolutionary constrained regions (ECRs) for CYP2C9: view image
Alliance of Genome Resources:
Additional Orthologs for CYP2C9

Paralogs for CYP2C9 Gene

Paralogs for CYP2C9 Gene

(38) SIMAP similar genes for CYP2C9 Gene using alignment to 12 proteins:

  • CP2C9_HUMAN
  • Q5EDC5_HUMAN
  • Q6IRV8_HUMAN
  • Q8WW80_HUMAN
  • Q9UEH3_HUMAN
  • Q9UQ59_HUMAN
  • S5R8G8_HUMAN
  • S5R8H1_HUMAN
  • S5RG22_HUMAN
  • S5RV20_HUMAN
  • S5RV29_HUMAN
  • S5RXA4_HUMAN
genes like me logo Genes that share paralogs with CYP2C9: view

Variants for CYP2C9 Gene

Products:

  1. SNP Genotyping and Copy Number Assays for research

Sequence variations, with clinical significance, from ClinVar and Humsavar, with links to dbSNP for CYP2C9 Gene

SNP ID Clinical significance and condition Chr 10 pos Variation AA Info Type
rs1057910 Drug Response: acenocoumarol response - Toxicity/ADR; Warfarin response; Glipizide response; Tolbutamide response; Phenytoin response; acenocoumarol response - Dosage, Toxicity/ADR; Antiinflammatory agents, non-steroids response - Toxicity/ADR; celecoxib response - Dosage; celecoxib response - Toxicity/ADR; diclofenac response - Toxicity/ADR; warfarin response - Dosage; warfarin response - Toxicity/ADR; Lesinurad response; Flurbiprofen response; Piroxicam response; not provided 94,981,296(+) A/Cp.Ile359Leu
CYP2C9*3 		MISSENSE
rs144043022 Likely Benign: not provided 94,941,953(+) T/C
NM_000771.4(CYP2C9):c.264T>C (p.Ile88=) 		SYNONYMOUS
rs1799853 Drug Response: warfarin response - Efficacy, Toxicity/ADR; Warfarin response; Phenytoin response; not specified; warfarin response - Dosage; Lesinurad response; Flurbiprofen response; Piroxicam response; not provided 94,942,290(+) C/Tp.Arg144Cys
CYP2C9*2 		MISSENSE
rs199741616 Likely Benign: not provided 94,988,863(+) G/T
NM_000771.4(CYP2C9):c.1308G>T (p.Val436=) 		SYNONYMOUS
rs2017319 Benign: not provided 94,988,878(+) C/T
NM_000771.4(CYP2C9):c.1323C>T (p.Ala441=) 		SYNONYMOUS

dbSNP identifiers (rs#s) for variants without ClinVar clinical significance for CYP2C9 Gene

All consequence types are included: molecular consequences (e.g. missense, synonymous), and location-based (e.g. intron, upstream).

Structural Variations from Database of Genomic Variants (DGV) for CYP2C9 Gene

Variant ID Type Subtype PubMed ID
esv2674280 CNV deletion 23128226
esv2739707 CNV deletion 23290073
esv2741937 CNV deletion 23290073
esv3624264 CNV gain 21293372
esv3624265 CNV gain 21293372
esv3891886 CNV loss 25118596
nsv1035409 CNV loss 25217958
nsv1047782 CNV gain 25217958
nsv551962 CNV loss 21841781
nsv551963 CNV loss 21841781
nsv7497 CNV insertion 18451855

Variation tolerance for CYP2C9 Gene

Residual Variation Intolerance Score: 87.8% of all genes are more intolerant (likely to be disease-causing)
Gene Damage Index Score: 6.04; 75.09% of all genes are more intolerant (likely to be disease-causing)

Additional Variant Information for CYP2C9 Gene

The Human Cytochrome P450 Allele Nomenclature Database
CYP2C9
Human Gene Mutation Database (HGMD)
CYP2C9
SNPedia medical, phenotypic, and genealogical associations of SNPs for
CYP2C9
Leiden Open Variation Database (LOVD)
CYP2C9

SNP Genotyping and Copy Number Assays for research

No data available for Polymorphic Variants from UniProtKB/Swiss-Prot for CYP2C9 Gene

Disorders for CYP2C9 Gene

MalaCards: The human disease database

(44) MalaCards diseases for CYP2C9 Gene - From: OMI, CVR, GTR, COP, and GCD

Disorder Aliases PubMed IDs
coumarin resistance
  • coumarin, poor metabolism of
diffuse alveolar hemorrhage
drug-induced hepatitis
  • drug-induced chronic hepatitis
diaphragm disease
  • abnormality of the diaphragm
small intestine diverticulitis
  • diverticulosis of small intestine with hemorrhage
- elite association - COSMIC cancer census association via MalaCards

Additional Disease Information for CYP2C9

Human Genome Epidemiology Navigator
(HuGE)
Atlas
ATLAS of Genetics and Cytogenetics in Oncology and Haematology
Open Targets Platform
Open Targets Platform
genes like me logo Genes that share disorders with CYP2C9: view

No data available for UniProtKB/Swiss-Prot and Genatlas for CYP2C9 Gene

Publications for CYP2C9 Gene

  1. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. (PMID: 18698879) Stehle S … Fuhr U (Clinical pharmacokinetics 2008) 3 22 25 40
  2. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. (PMID: 15606435) Zhang Y … Zhou H (British journal of clinical pharmacology 2005) 3 22 25 40
  3. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. (PMID: 20089352) Tan L … Yu Y (Clinical neurology and neurosurgery 2010) 3 22 40
  4. CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin. (PMID: 20445534) Carbonell N … Becquemont L (Clinical pharmacology and therapeutics 2010) 3 22 40
  5. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. (PMID: 20179710) Bray J … Boddy AV (British journal of cancer 2010) 3 22 40

ExternalLinks

View latest publications for CYP2C9 gene in Mastermind

Products for CYP2C9 Gene

Sources for CYP2C9 Gene